163 related articles for article (PubMed ID: 32891353)
1. Spinal metastases from lung cancer: Survival depends only on genotype, neurological and personal status, scarcely of surgical resection.
Amelot A; Terrier LM; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Bonaccorsi R; Le Nail LR; Mathon B
Surg Oncol; 2020 Sep; 34():51-56. PubMed ID: 32891353
[TBL] [Abstract][Full Text] [Related]
2. Survival in breast cancer patients with spine metastases: Prognostic assessment involving molecular markers.
Amelot A; Terrier LM; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Bonaccorsi R; Le Nail LR; Mathon B
Eur J Surg Oncol; 2020 Jun; 46(6):1021-1027. PubMed ID: 31899046
[TBL] [Abstract][Full Text] [Related]
3. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
4. Preoperative palsy score has no significant association with survival in non-small-cell lung cancer patients with spinal metastases who undergo spinal surgery.
Chen YJ; Chen HT; Hsu HC
J Orthop Surg Res; 2015 Sep; 10():149. PubMed ID: 26381378
[TBL] [Abstract][Full Text] [Related]
5. Spinal metastases from thyroid cancer: Some prognostic factors.
Planty-Bonjour A; Dubory A; Terrier LM; Taïbi T; Cook AR; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Le Nail LR; Mathon B; Amelot A
Eur J Surg Oncol; 2022 Jan; 48(1):292-298. PubMed ID: 34503849
[TBL] [Abstract][Full Text] [Related]
6. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
7. Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
Balasubramanian SK; Sharma M; Venur VA; Schmitt P; Kotecha R; Chao ST; Suh JH; Angelov L; Mohammadi AM; Vogelbaum MA; Barnett GH; Jia X; Pennell NA; Ahluwalia MS
Neuro Oncol; 2020 Feb; 22(2):267-277. PubMed ID: 31648302
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
9. Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis.
Zang S; He Q; Bao Q; Shen Y; Zhang W
Int J Clin Oncol; 2019 Sep; 24(9):1049-1060. PubMed ID: 31028506
[TBL] [Abstract][Full Text] [Related]
10. Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.
Park SJ; Lee CS; Chung SS
Spine J; 2016 Mar; 16(3):322-8. PubMed ID: 26586194
[TBL] [Abstract][Full Text] [Related]
11. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
Gutiérrez L; Royuela A; Carcereny E; López-Castro R; Rodríguez-Abreu D; Massuti B; González-Larriba JL; García-Campelo R; Bosch-Barrera J; Guirado M; Camps C; Dómine M; Bernabé R; Casal J; Oramas J; Ortega AL; Sala MA; Padilla A; Aguiar D; Juan-Vidal O; Blanco R; Del Barco E; Martínez-Banaclocha N; Benítez G; de Vega B; Hernández A; Saigi M; Franco F; Provencio M
BMC Cancer; 2021 Aug; 21(1):977. PubMed ID: 34465283
[TBL] [Abstract][Full Text] [Related]
12. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
[TBL] [Abstract][Full Text] [Related]
13. Spine Metastasis in Elderly: Encouraging Results for Better Survival.
Beaufort Q; Terrier LM; Dubory A; Le Nail LR; Cook AR; Cristini J; Buffenoir K; Pascal-Moussellard H; Carpentier A; Mathon B; Amelot A
Spine (Phila Pa 1976); 2021 Jun; 46(11):751-759. PubMed ID: 33332789
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on EGFR/ALK gene status and first-line targeted therapy rate in newly diagnosed advanced non-small cell lung cancer patients in Northern China: A prospective observational study.
Liang H; Song X; Zhang Y; Zhang S; Li F; Fang J; Li J; Liang L; Nie L; Ma K; Zhang L; Wang X; Xu J; Wei Y; Wang J; Song Q; Tian G; Mu Y; Gu Y; Yang L; Sun P; Zhong W; Zhao J; Xu Y; Chen M; Wang M
Thorac Cancer; 2019 Jul; 10(7):1521-1532. PubMed ID: 31144459
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Renaud S; Seitlinger J; Guerrera F; Reeb J; Beau-Faller M; Voegeli AC; Siat J; Clément-Duchêne C; Tiotiu A; Santelmo N; Costardi L; Ruffini E; Falcoz PE; Vignaud JM; Massard G
Ann Surg Oncol; 2018 Apr; 25(4):1069-1078. PubMed ID: 29362963
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer
in Different Genotypes].
Liu P; Wu Y; Zhou L; Qin N; Zhang Q; Zhang H; Li X; Zhang X; Lv J; Yang X; Wang J; Zhang S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):741-750. PubMed ID: 29167003
[TBL] [Abstract][Full Text] [Related]
17. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
18. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
19. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
[TBL] [Abstract][Full Text] [Related]
20. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
